Cerus ( Cerus )


Cerus's picture

About Cerus

We are developing and commercializing novel, proprietary products and technologies that are intended to make the blood supply safer. We are commercializing the INTERCEPT Blood System for platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT Blood System for platelets and plasma is not yet approved for sale in the United States. In 2008, we initiated a Phase I clinical trial for our INTERCEPT Blood System for red blood cells in the United States. The INTERCEPT Blood System, which is based on our proprietary Helinx technology for controlling biological replication, is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.

Cerus press release, blog etc

10/12/2018 - 15:41 Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting
10/11/2018 - 17:23 Dr. Laurence Corash Recognized With the Prestigious Dale A. Smith Memorial Award
10/09/2018 - 08:55 Cerus Appoints Eric Bjerkholt to Board of Directors
10/02/2018 - 00:09 Cerus to Host Institutional Investor Meeting
09/06/2018 - 04:54 Cerus Appoints Timothy L. Moore to Board of Directors
07/10/2018 - 09:06 New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis Platelets Collected at U.S. Navy Blood Donor Centers
06/15/2018 - 08:29 Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association
06/01/2018 - 07:33 Cerus Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th International Congress of the International Society of Blood Transfusion
05/16/2018 - 14:00 Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
04/25/2018 - 06:32 Cerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets
04/02/2018 - 08:17 Cerus RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.
03/13/2018 - 05:34 Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
02/02/2018 - 15:07 Cerus Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares
01/31/2018 - 07:20 Cerus Announces Pricing of Public Offering of Common Stock
01/30/2018 - 17:23 Cerus Announces Public Offering of Common Stock
11/07/2017 - 15:52 Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study
10/31/2017 - 07:47 Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy
10/30/2017 - 08:26 Cerus Announces Agreement with Transfusion Center of the Community of Madrid